Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling

British Journal of Clinical Pharmacology

Volumn 78, Issue 3, 2014, Pages 509-523

  Størset, Elisabet ^a,b   Holford, Nick ^c   Hennig, Stefanie ^d,e   Bergmann, Troels K ^d,f   Bergan, Stein ^b,g   Bremer, Sara ^g   Åsberg, Anders ^a,b   Midtvedt, Karsten ^a   Staatz, Christine E ^d,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e Australian Centre of Pharmacometrics   (Australia)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bayesian forecasting; kidney transplantation; population pharmacokinetics; tacrolimus; theory based models

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

ADULT; AGED; ARTICLE; AUSTRALIA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FAT FREE MASS; FEMALE; HEMATOCRIT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NORWAY; PHARMACOKINETICS; PREDICTION; PRIORITY JOURNAL; THEORETICAL MODEL; BAYES THEOREM; BIOAVAILABILITY; BIOLOGICAL MODEL; COMPARATIVE STUDY; GENETICS; GENOTYPE; MIDDLE AGED;

ADULT; BAYES THEOREM; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDNISOLONE; TACROLIMUS;

EID: 84906500898     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12361     Document Type: Article

References (51)

1. Staatz CE, Tett SE,. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623-653. (Pubitemid 38981845)
2. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, Kuypers D, Le Meur Y, Marquet P, Oellerich M, Thervet E, Toenshoff B, Undre N, Weber LT, Westley IS, Mourad M,. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009; 31: 139-152.
3. Saint-Marcoux F, Woillard J-B, Jurado C, Marquet P,. Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. Ther Drug Monit 2013; 35: 322-327.
4. Sheiner LB, Beal S, Rosenberg B, Marathe VV,. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 26: 294-305. (Pubitemid 10194671)
5. Staatz CE, Tett SE,. Maximum a posteriori Bayesian estimation of mycophenolic acid area under the concentration-time curve: is this clinically useful for dosage prediction yet? Clin Pharmacokinet 2011; 50: 759-772.
6. Bergmann TK, Hennig S, Barraclough KA, Isbel NM, Staatz CE,. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Impact of CYP3A5 genotype on starting dose. Ther Drug Monit 2014; 36: 62-70.
7. Størset E, Holford N, Midtvedt K, Bremer S, Bergan S, Åsberg A,. Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol 2014; 70: 65-77.
8. Han N, Yun H-Y, Hong J-Y, Kim I-W, Ji E, Hong SH, Kim YS, Ha J, Shin WG, Oh JM,. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. Eur J Clin Pharmacol 2013; 69: 53-63.
9. Woillard JB, de Winter BC, Kamar N, Marquet P, Rostaing L, Rousseau A,. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations-twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol 2011; 71: 391-402.
10. Passey C, Birnbaum AK, Brundage RC, Oetting WS, Israni AK, Jacobson PA,. Dosing equation for tacrolimus using genetic variants and clinical factors. Br J Clin Pharmacol 2011; 72: 948-957.
11. Staatz CE, Willis C, Taylor PJ, Tett SE,. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002; 72: 660-669. (Pubitemid 36021005)
12. Antignac M, Barrou B, Farinotti R, Lechat P, Urien S,. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 2007; 64: 750-757. (Pubitemid 350222052)
13. Benkali K, Premaud A, Picard N, Rerolle JP, Toupance O, Hoizey G, Turcant A, Villemain F, Le Meur Y, Marquet P, Rousseau A,. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet 2009; 48: 805-816.
14. Musuamba FTF, Mourad MM, Haufroid VV, Demeyer MM, Capron AA, Delattre IKI, Delaruelle FF, Wallemacq PP, Verbeeck RKR,. A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic acid and tacrolimus early after renal transplantation. J Clin Pharmacol 2011; 52: 1833-1843.
15. Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, Hartigh J, Paul LC, de Fijter JW,. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 2005; 67: 2440-2447. (Pubitemid 41623408)
16. Press RR, Ploeger BA,. Hartigh den J, van der Straaten T, van Pelt J, Danhof M, de Fijter JW, Guchelaar HJ. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 2009; 31: 187-197.
17. Elens L, Hesselink DA, van Schaik RHN, van Gelder T,. The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. Br J Clin Pharmacol 2013; 75: 1545-1547.
18. Boughton O, Borgulya G, Cecconi M, Fredericks S, Moreton-Clack M, MacPhee IAM,. A published pharmacogenetic algorithm was poorly predictive of tacrolimus clearance in an independent cohort of renal transplant recipients. Br J Clin Pharmacol 2013; 76: 425-431.
19. Antignac M, Fernandez C, Barrou B, Roca M, Favrat J-L, Urien S, Farinotti R,. Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients. Eur J Drug Metab Pharmacokinet 2011; 36: 25-33.
20. Willis C, Staatz CE, Tett SE,. Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients. Ther Drug Monit 2003; 25: 158-166. (Pubitemid 36373422)
21. Barraclough KA, Isbel NM, Kirkpatrick CM, Lee KJ, Taylor PJ, Johnson DW, Campbell SB, Leary DR, Staatz CE,. Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. Br J Clin Pharmacol 2011; 71: 207-223.
22. Svensson E, van der Walt J-S, Barnes KI, Cohen K, Kredo T, Huitema A, Nachega JB, Karlsson MO, Denti P,. Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. Br J Clin Pharmacol 2012; 74: 465-476.
23. Danhof M, de Lange ECM, Pasqua Della OE, Ploeger BA, Voskuyl RA,. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 2008; 29: 186-191.
24. Taylor PJ, Franklin ME, Tai C-H, Pillans PI,. Journal of Chromatography B. Therapeutic drug monitoring of tacrolimus by liquid chromatography-tandem mass spectrometry: is it truly a routine test? J Chromatogr B Analyt Technol Biomed Life Sci 2012; 883-884: 108-112.
25. Wallemacq P, Goffinet J-S, O'Morchoe S, Rosiere T, Maine GT, Labalette M, Aimo G, Dickson D, Schmidt E, Schwinzer R, Schmid RW,. Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. Ther Drug Monit 2009; 31: 198-204.
26. Vethe NT, Gjerdalen LC, Bergan S,. Determination of cyclosporine, tacrolimus, sirolimus and everolimus by liquid chromatography coupled to electrospray ionization and tandem mass spectrometry: assessment of matrix effects and assay performance. Scand J Clin Lab Invest 2010; 70: 583-591.
27. Cogill JL, Taylor PJ, Westley IS, Morris RG, Lynch SV, Johnson AG,. Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. Clin Chem 1998; 44: 1942-1946. (Pubitemid 28405760)
28. Beal SL, Sheiner LB, Boeckmann A, Bauer RJ,. NONMEM User's Guides. Ellicott City, MD, USA: Icon Development Solutions, 1989-2010.
29. Holford NHG,. Wings for NONMEM v. 720 for NONMEM 7.2. 2011. Available at: http://wfn.sourceforge.net/ (accessed 17 March 2014).
30. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2013; Available at: ISBN 3-900051-07-0. http://www.R-project.org/ (accessed 17 March 2014).
31. West GB, Brown JH, Enquist BJ,. A general model for the origin of allometric scaling laws in biology. Science 1997; 276: 122-126. (Pubitemid 27161259)
32. McCune J, Bemer M, Barrett J, Baker S, Gamis A, Holford NHG,. Busulfan in infants to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res 2014; 20: 754-763.
33. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B,. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-1065. (Pubitemid 41356391)
34. Anderson BJ, Holford NHG,. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24: 25-36.
35. Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, Lee CC, Schechter P, Mekki QA,. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281-290.
36. Christians U, Jacobsen W, Benet LZ, Lampen A,. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813-851.
37. Magnusson MO, Karlsson MO, Sandström R,. A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat. Pharm Res 2006; 23: 521-532.
38. Magnusson MO, Dahl M-L, Cederberg J, Karlsson MO, Sandström R,. Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. Clin Pharmacol Ther 2008; 84: 52-62. (Pubitemid 351861485)
39. Efron B,. Bootstrap methods: another look at the jackknife. Ann Stat 1979; 7: 1-26.
40. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143-151.
41. Sheiner LB, Beal SL,. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-512.
42. Holford NHG, Buclin T,. Safe and effective variability- A criterion for dose individualization. Ther Drug Monit 2012; 34: 565-568.
43. Staatz CE, Goodman LK, Tett SE,. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 2010; 49: 141-175.
44. Ekberg H, Mamelok RD, Pearson TC, Vincenti F, Tedesco-Silva H, Daloze P,. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony Study. Transplantation 2009; 87: 1360-1366.
45. Aarons L,. Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br J Clin Pharmacol 2005; 60: 581-583. (Pubitemid 41705376)
46. Hebert MF, Zheng S, Hays K, Shen DD, Davis CL, Umans JG, Miodovnik M, Thummel KE, Easterling TR,. Interpreting tacrolimus concentrations during pregnancy and postpartum. Transplantation 2013; 95: 908-915.
47. Sam WJ, Tham LS, Holmes MJ, Aw M, Quak SH, Lee KH, Lim SG, Prabhakaran K, Chan SY, Ho PC,. Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients. Clin Pharmacokinet 2006; 45: 59-75. (Pubitemid 43145015)
48. Bekersky I, Dressler D, Mekki Q,. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 2001; 41: 289-297. (Pubitemid 32184981)
49. Elens L, Bouamar R, Shuker N, Hesselink DA, van Gelder T, van Schaik RHN,. Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. Br J Clin Pharmacol 2014; 77: 715-728.
50. Savic RM, Karlsson MO,. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 2009; 11: 558-569.
51. Bouamar R, Shuker N, Hesselink DA, Weimar W, Ekberg H, Kaplan B, Bernasconi C, van Gelder T,. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials. Am J Transplant 2013; 13: 1253-1261.